Quantitative Washout in Patients with Hepatocellular Carcinoma Undergoing TACE: an Imaging Biomarker for Predicting Prognosis?

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2022 Jan 12

PMID 35016731

Authors

Lukas Muller

Felix Hahn

Florian Jungmann

Aline Mahringer-Kunz

Fabian Stoehr

Moritz C Halfmann

Daniel Pinto Dos Santos

Jan Hinrichs

Timo A Auer

Christoph Duber

Roman Kloeckner

Affiliations

Soon will be listed here.

Abstract

Background: The delayed percentage attenuation ratio (DPAR) was recently identified as a novel predictor of an early complete response in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). In this study, we aimed to validate the role of DPAR as a predictive biomarker for short-, mid-, and long-term outcomes after TACE.

Methods: We retrospectively reviewed laboratory and imaging data for 103 treatment-naïve patients undergoing initial TACE treatment at our tertiary care center between January 2016 and November 2020. DPAR and other washin and washout indices were quantified in the triphasic computed tomography performed before the initial TACE. The correlation of DPAR and radiologic response was investigated. Furthermore, the influence of DPAR on the 6-, 12-, 18-, and 24-month survival rates and the median overall survival (OS) was compared to other established washout indices and estimates of tumor burden and remnant liver function.

Results: The DPAR was significantly of the target lesions (TLs) with objective response to TACE after the initial TACE session was significantly higher compared to patients with stable disease (SD) or progressive disease (PD) (125 (IQR 118-134) vs 110 (IQR 103-116), p < 0.001). Furthermore, the DPAR was significantly higher in patients who survived the first 6 months after TACE (122 vs. 115, p = 0.04). In addition, the number of patients with a DPAR > 120 was significantly higher in this group (n = 38 vs. n = 8; p = 0.03). However, no significant differences were observed in the 12-, 18-, and 24-month survival rates after the initial TACE. Regarding the median OS, no significant difference was observed for patients with a high DPAR compared to those with a low DPAR (18.7 months vs. 12.7 months, p = 0.260).

Conclusions: Our results confirm DPAR as the most relevant washout index for predicting the short-term outcome of patients with HCC undergoing TACE. However, DPAR and the other washout indices were not predictive of mid- and long-term outcomes.

Citing Articles

Quantum iterative reconstruction on a photon-counting detector CT improves the quality of hepatocellular carcinoma imaging.

Graafen D, Stoehr F, Halfmann M, Emrich T, Foerster F, Yang Y Cancer Imaging. 2023; 23(1):69.

PMID: 37480062 PMC: 10362630. DOI: 10.1186/s40644-023-00592-5.

Rim Enhancement after Technically Successful Transarterial Chemoembolization in Hepatocellular Carcinoma: A Potential Mimic of Incomplete Embolization or Reactive Hyperemia?.

Ekert K, Kloth C, Nikolaou K, Grozinger G, Horger M, Thaiss W Tomography. 2022; 8(2):1148-1158.

PMID: 35448728 PMC: 9028792. DOI: 10.3390/tomography8020094.

References

Mahringer-Kunz A, Kloeckner R, Pitton M, Duber C, Schmidtmann I, Galle P . Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2017; 40(7):1017-1025. DOI: 10.1007/s00270-017-1606-4. View

Vesselle G, Quirier-Leleu C, Velasco S, Charier F, Silvain C, Boucebci S . Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol. 2015; 26(6):1640-8. DOI: 10.1007/s00330-015-3982-y. View

Kim B, Shim J, Kim S, Park J, Kim D, Ahn S . Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. Liver Int. 2015; 36(1):92-9. DOI: 10.1111/liv.12865. View

Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M . Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019; 70(5):893-903. DOI: 10.1016/j.jhep.2019.01.013. View

Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso J . Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2007; 47(1):97-104. DOI: 10.1002/hep.21966. View

Llovet J, Bru C, Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3):329-38. DOI: 10.1055/s-2007-1007122. View

Purcell Y, Sartoris R, Paradis V, Vilgrain V, Ronot M . Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. J Gastroenterol Hepatol. 2019; 35(2):305-313. DOI: 10.1111/jgh.14816. View

Peng J, Kang S, Ning Z, Deng H, Shen J, Xu Y . Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging. Eur Radiol. 2019; 30(1):413-424. PMC: 6890698. DOI: 10.1007/s00330-019-06318-1. View

Yoon S, Lee J, So Y, Hong S, Kim S, Han J . Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol. 2009; 193(6):W482-9. DOI: 10.2214/AJR.08.1818. View

10.

Collins G, Reitsma J, Altman D, Moons K . Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. The TRIPOD Group. Circulation. 2015; 131(2):211-9. PMC: 4297220. DOI: 10.1161/CIRCULATIONAHA.114.014508. View

11.

Heimbach J, Kulik L, Finn R, Sirlin C, Abecassis M, Roberts L . AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; 67(1):358-380. DOI: 10.1002/hep.29086. View

12.

Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Muller C . The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology. 2013; 57(6):2261-73. DOI: 10.1002/hep.26256. View

13.

Iannaccone R, Laghi A, Catalano C, Rossi P, Mangiapane F, Murakami T . Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology. 2005; 234(2):460-7. DOI: 10.1148/radiol.2342031202. View

14.

Zhang W, Xu A, Wang W, Wu Y, Sun Q, Shu C . Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation. BMC Cancer. 2019; 19(1):1041. PMC: 6833151. DOI: 10.1186/s12885-019-6265-1. View

15.

Labeur T, Takkenberg R, Klumpen H, van Delden O . Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2018; 42(2):230-238. PMC: 6344387. DOI: 10.1007/s00270-018-2118-6. View

16.

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

17.

Chernyak V, Fowler K, Kamaya A, Kielar A, Elsayes K, Bashir M . Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018; 289(3):816-830. PMC: 6677371. DOI: 10.1148/radiol.2018181494. View

18.

Lee C, Kim K, Lee J, Park Y, Choi J, Park C . Using low tube voltage (80kVp) quadruple phase liver CT for the detection of hepatocellular carcinoma: two-year experience and comparison with Gd-EOB-DTPA enhanced liver MRI. Eur J Radiol. 2012; 81(4):e605-11. DOI: 10.1016/j.ejrad.2011.12.033. View

19.

Hiraoka A, Kumada T, Kudo M, Hirooka M, Koizumi Y, Hiasa Y . Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. Dig Dis. 2017; 35(6):602-610. DOI: 10.1159/000480256. View

20.

Kloeckner R, Weinmann A, Prinz F, Pinto Dos Santos D, Ruckes C, Dueber C . Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer. 2015; 15:465. PMC: 4460638. DOI: 10.1186/s12885-015-1480-x. View